Will Scotton

Come and work with us at RWT! Job advert for senior clinical fellow in the Neurology team www.nhsjobs.com/job/UK/Birmi...

Consultant in Neurology - Wolverhampton job with The Royal Wolverhampton NHS Trust | 713059 Seeking a Consultant in Neurology joining 10 consultants in the Neurology Directorate covering Wolverhampton, Staffordshire & Shropshire.

Job alert! Come and join an ambitious and growing department with supportive colleagues and plenty of scope for building subspecialty interests.. beautiful surrounding South Staffs and Shropshire countryside and also host the NIHR WM RRDN www.bmj.com/careers/job/...

How Do I Diagnose Multiple System Atrophy—A Videolibrary on Clinical and Imaging Features Click on the article title to read more.

movementdisorders.onlinelibrary.wiley.com/doi/full/10....

UK DTN Engagement and Communications Lead Join Prof Cath Mummery's team at UCL, driving strategic communications for the UK Dementia Trials Network to shape dementia research across the UK.

Exciting communications role at UCL with Prof Cath Mummery, shaping strategic engagement for the UK Dementia Trials Network. Advance dementia research nationwide! Closing date: 18th June

www.dementiaresearcher.nihr.ac.uk/job/uk-dtn-e...

MPs sound alarm over neurologist shortage MPs have urged the Government to urgently tackle a “severe shortage” of neurologists in the NHS, warning that the shortfall is contributing to delays in diagnosis and compromised care for people with ...

thelimbus.co.uk/neurology/mp...

Abn were already sounding the alarm 5 years ago..

12 months of full
Immersion. Sad that its over en.m.wikipedia.org/wiki/Aubrey%...

Environmental Factors Environmental exposures linked to Parkinson's disease that scientists are working to better understand.

A strong link has been shown between Parkinson's disease and exposure to pesticides and herbicides. Learn more about environmental causes of PD: Parkinson.org/understanding-parkinsons/causes/environmental-factors

Reads: “For more than 100 years, doctors have known that the eyes can be used as a window to the rest of the body. Now, thanks to the power of AI and big data, we can find information hidden within retinal images and use this information to pick up early signs of neurodegenerative diseases.”

How might AI help us to detect dementia through retinal scans? 👀
We spoke to Professor Pearse Keane (@ucleye.bsky.social) about pioneering studies in the emerging field of #oculomics.
➡️ bit.ly/3XuReOH
@moorfieldsbrc.bsky.social #UCLDementia #DementiaActionWeek

Wow!

We are doing a survey to understand why other professionals do/don't refer people with Primary Progressive Aphasia for speech-language support

We want Drs, nurses, psychologists, social workers, OTs, PTs & any other profession.

The survey can be accessed here: qualtrics.ucl.ac.uk/jfe/form/SV_...

UCL – University College London UCL is consistently ranked as one of the top ten universities in the world (QS World University Rankings 2010-2022) and is No.2 in the UK for research power (Research Excellence Framework 2021).

Hiring! We're looking for a postdoc to join my lab at the @ukdri.ac.uk @ucl.ac.uk We’re investigating neuronal and circuit dysfunction in Alzheimer's, and developing innovative new treatments.

Apply here👇
shorturl.at/LpCAq

Dr. Alfonso Fasano, a neurologist at University Health Network in Toronto, talks with Dwyer. (Turgut Yeter/CBC)

Early results of an Adaptive Deep Brain Stimulation trial show promising improvements in speech, movement and quality of life for patients with #Parkinsons.

Learn more through the eyes of patient Fabio Dywer and #TeamUHN neurologist Dr. @alfonsofasano.bsky.social Fasano:
bit.ly/3F4bTCB

🚀 New study reveals how four different anti-amyloid drugs interact with amyloid beta protein. They found that lecanemab performed best in binding to small oligomeric forms of the amyloid protein, suggesting a working model for treating people in the earlier stages of Alzheimer’s (1/4)

Clinical criteria for limbic‐predominant age‐related TDP‐43 encephalopathy Limbic predominant age-related TDP-43 encephalopathy neuropathologic change (LATE-NC) is highly prevalent in late life and a common co-pathology with Alzheimer's disease neuropathologic change (ADNC...

I appreciated learning at the @wisconsinadrc.bsky.social ADRD Research Day about new criteria for limbic-predominant age-related TDP-43 encephalopathy (LATE).

LATE has been recently been identified as a fairly common cause of memory loss.

alz-journals.onlinelibrary.wiley.com/doi/full/10....

💻 Upcoming #webinar on “Recent Advances in Clinical Trials in Multiple System Atrophy”
📅 20th May, 3:00 CEST
🗣️ David Bendetowicz, University Hospital Bordeaux, France
Sign up 👉 https://t1p.de/ri7k3
Joint with the European Reference Network for Rare Neuromuscular Diseases and @ean.org

Morphologically distinct TDP-43 aggregates. Representative photomicrographs (mag 40×) from the anterior horn of the cervical spinal cord of patients with amyotrophic lateral sclerosis (as described by Spence et al) and a healthy control individual. Copyright: 2025 Elsevier Ltd. All rights reserved.

Genetic mutations contribute to a small but significant portion of Amyotrophic lateral sclerosis (ALS) cases.

A new @thelancetneuro.bsky.social Series summarises groundbreaking research on genetic ALS, offering insights into potential treatments: tinyurl.com/544kx3fu

With so many great tau researchers like @leatgrinberg.bsky.social @lucbuee.bsky.social @sjorsscheres.bsky.social @selinawray.bsky.social @karchlab.bsky.social on #SciSky could not help but put together my 1st starterpack⤵️

We are all fighting for you @curemaptftd.bsky.social 💙

go.bsky.app/KHno2VG

A first in human genomics: a 4-generation pedigree reference, now in Nature.

Built with #PacBio HiFi, it maps de novo mutation rates, reveals paternal bias, and captures high mutation rates in tandem repeats—even in Y and repeat-rich regions.

Paper here: go.nature.com/4lGMPlP

#TheresHiFiForThat

AI tool can track effectiveness of multiple sclerosis treatments A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers.

#ICYMI A new AI tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by @uclqsion.bsky.social researchers.
buff.ly/bXwvg35

Final programme for this event is now available! www.ucl.ac.uk/ion/events/2...

🚨Fantastic job opportunity for neurology trainees

Neurology Clinical Lecturer post in Dementia with us @qmuldementia.bsky.social now open to applications!

Please DM me for info and to discuss

www.oriel.nhs.uk/Web/PermaLin...

"In the absence of replication, together with private conversations, such papers used to quietly die. Now they are being publicly murdered. I am not sure which is the better way." - Prof John Hardy

www.alzforum.org/papers/bad-m...

MND Advancing Treatment Awards - DEMENTIA RESEARCHER The My Name’5 Doddie Foundation Advancing Treatments Award will support the early-stage development of new treatments to slow, stop or reverse MND progression

Accelerate your MND research from lab to patient! Up to £500k available through My Name’5 Doddie Foundation's 2025 Advancing Treatments Award. #MotorNeuroneDisease @mndoddie5.bsky.social

www.dementiaresearcher.nihr.ac.uk/funding/mnd-...

2-weeks till PPA awareness day 4 April!

Webinar link: speechtherapyppa.com/ppa-awarenes...

This wk we are sharing another podcast, this time created with student speech & language therapists abt the UCL PPA clinic: podcasts.apple.com/gb/podcast/e...

#PPAawareness
@ppaphasiaawareness.bsky.social

UKDRI Group Leader/ Senior Research Associate Applications are invited for a Group Leader in the UK Dementia Research Institute at University of Cambridge, Department of Clinical Neurosciences

Applications are invited for a Group Leader in the @ukdri.ac.uk at the University of Cambridge, Department of Clinical Neurosciences, Cambridge Biomedical Campus. Closing date: 28th April

www.dementiaresearcher.nihr.ac.uk/job/ukdri-gr...

Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease - Molecular Neurodegeneration Background Aggregated alpha-Synuclein (αSyn) is a hallmark pathology in Parkinson’s disease but also one of the most common co-pathologies in Alzheimer’s disease (AD). Preclinical studies suggest that...

Excited to share our new work in Molecular Neurodegeneration, showing that α-synuclein co-pathology is common in Alzheimer’s and accelerates amyloid-related tau accumulation, supporting its role as a tau co-aggregation factor.

doi.org/10.1186/s130...

Unprecedented Combination of Rare Degenerative Pathologies in an Octogenarian Ex‐Football Player A 79-year-old former professional football player presented with language deficits and cognitive changes. A year later, he had difficulty completing sentences, and 3 years after onset, was reduced to....

😳😳 onlinelibrary.wiley.com/doi/10.1111/...

The number of patients entering clinical trials in the UK fell by 27% from 2018 to 2023 and new industry trials declined 38%.

To revive clinical research we need to streamline systems and dismantle bureaucracy, writes @masudhusain.bsky.social
www.bmj.com/content/388/...

Register for our WinterSchool with Bernhard Landwehrmeyer, who will be talking about Disease-Modifying Treatment Approaches/Trials in Huntington's Disease on March 12. In collaboration with the European Paediatric Neurology Society. Registration: https://t1p.de/eajix, Programme: https://t1p.de/jrxm9

At MSA Health & Care Professionals Study Day, Prof Henry Houlden provided an overview of MSA offering key insights for healthcare professionals. Dr Yee Yen Goh presented on how to diagnose MSA in patients, outlining key clinical markers & diagnostic approaches. @uclqsion.bsky.social